Média

Combined General Meeting on April 26, 2017

Paris (France), April 5, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today that Onxeo’s shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which is being held on Wednesday,…read more →

Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting

Preclinical studies of AsiDNA™, Livatag® and Beleodaq® Paris (France), March 21, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today the presentation of data from three studies supporting the company’s primary drug candidates in…read more →

Full-year 2016 Results and Outlook for 2017

Reinforcement of Onxeo’s strategic positioning in the development of innovative oncology treatments Acquisition of DNA Therapeutics and the AsiDNATM product, a first-in-class candidate in the new area of preventing tumor cells from repairing their DNA Enrolment for the phase III Livatag® study in advanced primary liver cancer completed on schedule to deliver preliminary results mid-2017 Cash and cash equivalents of…read more →

Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development

Françoise Bono, PhD, Named Chief Scientific Officer to Lead Preclinical Activities Olivier de Beaumont, MD, MBA, Appointed Chief Medical Officer to Lead Clinical Development and Operations, Medical and Regulatory Affairs Paris (France), March 1, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment…read more →

Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.

New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™  Paris (France), February 13, 2017 – 18:00 CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the U.S. Patent and Trademark…read more →

Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board

Paris (France), February 8, 2017 – 8.30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, wishes to clarify information regarding the ReLive trial design and conduct and, in particular, the role of its Data Safety and Monitoring…read more →

Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future

The Institut Curie and Onxeo join forces in this ambitious project that will benefit cancer patients Paris (France), Copenhagen (Denmark), January 31, 2017 – 08:30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, and the Institut Curie, a…read more →

Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma

Milestone completion in line with expected preliminary outcomes mid-2017  Paris (France), Copenhagen (Denmark), January 24, 2017 – 18:30 CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the completion of enrollment in ReLive, the international Phase III clinical…read more →

Meet the Onxeo Team during the 2017 J.P. Morgan Healthcare Conference

January 9-12, 2017 in San Francisco, CA  In 2016, Onxeo has achieved a number of significant milestones, positioning the Company for success in 2017 and beyond. With a robust pipeline focused on addressing unmet medical needs in the treatment of rare cancers, Onxeo is poised to become the leader in orphan oncology. Onxeo has a promising therapeutic pipeline with multiple…read more →

Onxeo to Attend Two French Investor Conferences in January

Oddo Investor Forum, January 5-6, 2017 in Lyon Invest Securities BioMed Event, January 26, 2017 in Paris  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the Company’s management will attend the Oddo Investor Forum,…read more →